Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies
Clinical trial NCT06383572 · RECRUITING
Trial details
- NCT number
- NCT06383572
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-26
- Primary completion
- 2027-04-01
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.